Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Inovio Pharmaceuticals Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.51, while Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BIL | INO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $2.87 |
52-Week Low | $91.27 | $0.66 |
Market Cap | — | $76.09M |
Enterprise Value | — | $47.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
